Dr Hugo Albrecht

Senior Lecturer in Pharmaceutical Science UniSA Clinical & Health Sciences

City West Campus (HB6-25)
tel +61 8 830 21093

email Hugo.Albrecht@unisa.edu.au

Research Degree Supervisor

About me

Anticancer drug discovery
Kinase inhibitors
Drug delivery & drug targeting
Nanoparticle-based drug carriers

Hugo Albrecht is a senior lecturer at the University of South Australia conducting research and teaching activities within the Academic Unit of Clinical & Health Sciences. After obtaining his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland, he has gained considerable experience in both commercial and academic settings in Europe and the US. He has focused his research efforts in the fields of cancer, immunology and neuroscience. For over 20 years, Hugo has been dedicated to preclinical pharmaceutical development. He has led over 20 major drug discovery projects while working in industry and academia. Hugo’s current focus is on the development of biochemical and cell-based assay systems, and animal... Read more

UniSA Clinical & Health Sciences

UniSA Clinical & Health Sciences is addressing society’s most critical and emerging health needs through quality teaching, learning and research excellence.

Tweets by @UniversitySA

Research

Research focus

Pharmacology and Pharmaceutical Sciences
Medicinal and Biomolecular Chemistry
Biochemistry and Cell Biology
Oncology and Carcinogenesis
Organic Chemistry

Research

Outputs

Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus

Open access indicates that an output is open access.

Highlights

Year	Output
2018	Kübler, E & Albrecht, H 2018, 'Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines', Oncotarget, vol. 9, no. 38, pp. 24882-24897. Open access 25
2018	Zhang, W, Song, Y, Eldi, P, Guo, X, Hayball, JD, Garg, S & Albrecht, H 2018, 'Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles', International Journal of Nanomedicine, vol. 13, pp. 293-305. Open access 35 26 5
2017	Zeleke, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of Medicinal Chemistry, vol. 60, no. 5, pp. 1892-1915. Open access 54 48 6
2016	Zhang, W, Garg, S, Eldi, P, Zhou, FH-h, Johnson, IR, Brooks, DA, Lam, F, Rychkov, G, Hayball, JD & Albrecht, H 2016, 'Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide', International Journal of Pharmaceutics, vol. 513, pp.270-279. 24 20 4
2014	Diab, S, Teo, THS, Kumarasiri, M, Li, P, Yu, M, Lam, F, MC Basnet, S, Sykes, MJ, Albrecht, H, Milne, R & Wang, S 2014, 'Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors : synthesis, SAR analysis and biological evaluation', ChemMedChem: chemistry enabling drug discovery, vol. 9, no. 5, pp. 962-972. Open access 66 62 1

Chapters

Year	Output
2012	de Wild, M, Muller, T, Tschumi, S, Schumacher, R & Albrecht, H 2012, 'Production and in-vitro characterization of micro-structured implant surfaces', in PJ Bartolo et al. (eds), Innovative developments in virtual and physical prototyping, CRC Press, UK, pp. 111-114. 1

Journal Articles

Year	Output
2023	Hussain, MS, Faisal, KS, Clulow, AJ, Albrecht, H, Krasowska, M & Blencowe, A 2023, 'Influence of lyophilization and cryoprotection on the stability and morphology of drug-loaded poly(ethylene glycol-b-ε-caprolactone) micelles', Polymers, vol. 15, no. 8, article no. 1974. Open access
2022	Anshabo, AT, Bantie, L, Diab, S, Lenjisa, J, Kebede, A, Long, Y, Heinemann, G, Karanjia, J, Noll, B, Basnet, SK, Li, M, Milne, R, Albrecht, H & Wang, S 2022, 'An orally bioavailable and highly efficacious inhibitor of CDK9/FLT3 for the treatment of acute myeloid leukemia', Cancers, vol. 14, no. 5, article no. 1113, pp. 1-19. Open access 3 2 2
2022	Khetan, R, Dharmayanti, C, Gillam, TA, Kübler, E, Klingler-Hoffmann, M, Ricciardelli, C, Oehler, MK, Blencowe, A, Garg, S & Albrecht, H 2022, 'Using GPCRs as molecular beacons to target ovarian cancer with nanomedicines', Cancers, vol. 14, no. 10, article no. 2362, pp. 1-32. Open access 3 3 7
2022	Teo, T, Kasirzadeh, S, Albrecht, H, Sykes, MJ, Yang, Y & Wang, S 2022, 'An overview of CDK3 in cancer: clinical significance and pharmacological implications', Pharmacological Research, vol. 180, pp. 1-15. 3 2 2
2021	Anshabo, AT, Milne, R, Wang, S & Albrecht, H 2021, 'CDK9: A comprehensive review of its biology, and its role as a potential target for anti-cancer agents', Frontiers in Oncology, vol. 11, article no. 678559, pp. 1-24. Open access 46 34 2
2021	Arafat, M, Fouladian, P, Wignall, A, Song, Y, Parikh, A, Albrecht, H, Prestidge, CA, Garg, S & Blencowe, A 2021, 'Development and in vitro evaluation of 5-fluorouracil-eluting stents for the treatment of colorectal cancer and cancer-related obstruction', Pharmaceutics, vol. 13, no. 1, article no. 17, pp. 1-22. Open access 13 10 1
2021	Arafat, M, Song, Y, Brewer, K, Fouladian, P, Parikh, A, Albrecht, H, Blencowe, A & Garg, S 2021, 'Pharmaceutical development of 5-fluorouracil-eluting stents for the potential treatment of gastrointestinal cancers and related obstructions', Drug Design Development and Therapy, vol. 15, pp. 1495-1507. Open access 3 5
2021	Dharmayanti, C, Gillam, TA, Klingler-Hoffmann, M, Albrecht, H & Blencowe, A 2021, 'Strategies for the development of pH-responsive synthetic polypeptides and polymer-peptide hybrids: recent advancements', Polymers, vol. 13, no. 4, article no. 624, pp. 1-16. Open access 22 16
2020	Bantie, L, Tadesse, S, Likisa, J, Yu, M, Noll, B, Heinemann, G, Lokman, NA, Ricciardelli, C, Oehler, MK, Beck, A, Pradhan, R, Milne, R, Albrecht, H & Wang, S 2020, 'A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer', Gynecologic Oncology, vol. 159, no. 3, pp. 827-838. 8 10 1
2019	Abdelaziz, AM, Diab, S, Islam, S, KC Basnet, S, Noll, B, Li, P, Mekonnen, LB, Lu, J, Albrecht, H, Milne, RW, Gerber, C, Yu, M & Wang, S 2019, 'Discovery of n-phenyl-4-(1h-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent mnk2 inhibitors: design, synthesis, sar analysis, and evaluation of in vitro anti-leukaemic activity', Medicinal Chemistry, vol. 15, no. 6, pp. 600-621. 6 5
2019	Abdelaziz, AM, MC Basnet, S, Islam, S, Li, M, Tadesse, S, Albrecht, H, Gerber, C, Yu, M & Wang, S 2019, 'Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors', Bioorganic and Medicinal Chemistry Letters, vol. 29, no. 18, pp. 2650-2654. Open access 9 7 3
2019	Albrecht, H & Kübler, E 2019, 'Systematic meta-analysis identifies co-expressed kinases and gpcrs in ovarian cancer tissues revealing a potential for targeted kinase inhibitor delivery', Pharmaceutics, vol. 11, no. 9, article no. 454 pp. 1-17. Open access 6 5 1
2019	Arafat, M, Fouladian, P, Blencowe, A, Albrecht, H, Song, Y & Garg, S 2019, 'Drug-eluting non-vascular stents for localised drug targeting in obstructive gastrointestinal cancers', Journal of Controlled Release, vol. 308, pp. 209-231. Open access 23 18 1
2019	Khair, NZ, Lenjisa, JL, Tadesse, S, Kumarasiri, M, Basnet, SK, Mekonnen, LB, Li, M, Diab, S, Sykes, MJ, Albrecht, H, Milne, R & Wang, S 2019, 'Discovery of CDK5 inhibitors through structure-guided approach', ACS Medicinal Chemistry Letters, vol. 10, no. 5, pp. 786-791. Open access 16 16 1
2018	Kübler, E & Albrecht, H 2018, 'Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines', Oncotarget, vol. 9, no. 38, pp. 24882-24897. Open access 25
2018	Zhang, W, Song, Y, Eldi, P, Guo, X, Hayball, JD, Garg, S & Albrecht, H 2018, 'Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles', International Journal of Nanomedicine, vol. 13, pp. 293-305. Open access 35 26 5
2017	Diab, S, Abdelaziz, AM, Li, P, Teo, T, Basnet, SK, Noll, B, Rahaman, MH, Lu, J, Hou, J, Yu, M, Le, BT, Albrecht, H, Milne, RW & Wang, S 2017, 'Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia', European Journal of Medicinal Chemistry, vol. 139, pp. 762-772. Open access 22 18
2017	Kumarasiri, M, Teo, T, Yu, M, Philip, S, Basnet, SK, Albrecht, H, Sykes, MJ, Wang, P & Wang, S 2017, 'In search of novel CDK8 inhibitors by virtual screening', Journal of Chemical Information and Modeling, vol. 57, no. 3, pp. 413-416. 14 15 2
2017	Lenjisa, JL, Tadesse, S, Khair, NZ, Kumarasiri, M, Yu, M, Albrecht, H, Milne, R & Wang, S 2017, 'CDK5 in oncology: recent advances and future prospects.', Future Medicinal Chemistry, vol. 9, no. 16, pp. 1939-1962. Open access 32 29
2017	Zeleke, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of Medicinal Chemistry, vol. 60, no. 5, pp. 1892-1915. Open access 54 48 6
2016	Diab, S, Li, P, MC Basnet, S, Lu, J, Yu, M, Albrecht, H, Milne, RW & Wang, S 2016, 'Unveiling new chemical scaffolds as Mnk inhibitors', Future Medicinal Chemistry, vol. 8, no. 3, pp. 271-285. 19 18
2016	Li, P, Diab, S, Yu, M, Adams, J, Islam, S, MC Basnet, S, Albrecht, H, Milne, RW & Wang, S 2016, 'Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells', Oncotarget, vol.7, no.35, pp.1-15. Open access 21 20
2016	Rahaman, MH, Kumarasiri, M, Mekonnen, LB, Yu, M, Diab, S, Albrecht, H, Milne, RW & Wang, S 2016, 'Targeting CDK9: a promising therapeutic opportunity in prostate cancer', Endocrine-Related Cancer, vol. 23, no. 12, pp. T211-T226. Open access 50 46 5
2016	Zhang, W, Garg, S, Eldi, P, Zhou, FH-h, Johnson, IR, Brooks, DA, Lam, F, Rychkov, G, Hayball, JD & Albrecht, H 2016, 'Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide', International Journal of Pharmaceutics, vol. 513, pp.270-279. 24 20 4
2015	MC Basnet, S, Diab, S, Schmid, R, Yu, M, Yang, Y, Gillam, TA, Teo, T, Li, P, Peat, T, Albrecht, H & Wang, S 2015, 'Identification of a highly conserved allosteric binding site on Mnk1 and Mnk2', Molecular Pharmacology, vol. 88, no. 5, pp. 935-948. Open access 15 15
2015	Teo, T, Lam, F, Yu, M, Yang, Y, MC Basnet, S, Albrecht, H, Sykes, M & Wang, S 2015, 'Pharmacologic inhibition of MNKs in acute myeloid leukemia', Molecular Pharmacology, vol. 88, no. 2, pp. 380-389. Open access 25 22 6
2015	Teo, T, Yang, Y, Yu, M, MC Basnet, S, Gillam, T, Hou, J, Schmid, R, Kumarasiri, M, Diab, S, Albrecht, H, Sykes, M & Wang, S 2015, 'An integrated approach for discovery of highly potent and selective Mnk inhibitors: screening, synthesis and SAR analysis', European Journal of Medicinal Chemistry, vol. 103, pp. 539-550. 27 25 4
2015	Yu, M, Li, P, MC Basnet, S, Kumarasiri, M, Diab, S, Teo, T, Albrecht, H & Wang, S 2015, 'Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d[pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation', European Journal of Medicinal Chemistry, vol. 95, pp. 116-126. 33 33 3
2014	Diab, S, Teo, THS, Kumarasiri, M, Li, P, Yu, M, Lam, F, MC Basnet, S, Sykes, MJ, Albrecht, H, Milne, R & Wang, S 2014, 'Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors : synthesis, SAR analysis and biological evaluation', ChemMedChem: chemistry enabling drug discovery, vol. 9, no. 5, pp. 962-972. Open access 66 62 1
2008	Joesch, C, Guevarra, E, Parel, S, Bergner, A, Zbinden, P, Konrad, D & Albrecht, H 2008, 'Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and µARCS technologies: Identification of ion channel modulators acting on the GABAA receptor', Journal of Biomolecular Screening, vol. 13, no. 3, pp. 218-228. 40 33

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Australian Synchrotron	AUSTRALIA
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation)	AUSTRALIA
Shandong University	CHINA
South Australian Health and Medical Research Institute (SAHMRI)	AUSTRALIA
University of Adelaide	AUSTRALIA
University of Applied Sciences and Arts Northwestern Switzerland	SWITZERLAND
University of Applied Sciences Northwestern Switzerland	SWITZERLAND
University of South Australia	AUSTRALIA
Yabao Pharmaceutical Group Co., Ltd	CHINA

Teaching & student supervision

Highlights

Drug discovery, Drug development

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
111081 - Introducing a new paradigm for specific targeting of ovarian cancer cells with engineered nanoparticles, using G protein-coupled receptors as molecular entry points	Current
111128 - Molecular mechanisms for growth plate cartilage degeneration after injury	Current
An In-Vivo analysis of combination therapy of PPIs and H2 Blocker induced potential bone loss in Sprague Dawley rats model	Current
Development of Cyclin Dependent Kinase Inhibitors for Cancer Treatment	Current
Development of novel stimuli-responsive polysaccharides as delivery systems	Current
Investigating the role of novel Tropomyosin receptor kinase (TRK) inhibitor for the treatment of NTRK fusion-positive lung cancer	Current
Overcoming the hurdles of drug delivery for ovarian cancer: Preparation of targeted and pH-responsive nanoparticles loaded with Kinase and PARP Inhibitors.	Current
Targeting ovarian cancer with nanoparticle drug carriers using G protein-coupled receptors as molecular entry sites	Current
Design, synthesis, and evaluation of novel CDK2 inhibitors as potential anticancer agents	Completed
Development of cyclin dependent kinase 9 inhibitors for the treatment of cancer	Completed
Development of drug-eluting stents for the localised delivery of 5-fluorouracil targeted towards the treatment of gastrointestinal cancers	Completed
Development of injectable hydrogels for the delivery of therapeutic agents	Completed
Identification and characterisation of Mnk inhibitors as potential anti-cancer agents	Completed
Novel cyclin-dependent kinase 9 inhibitors for the treatment of cancer: identification and preclinical evaluation	Completed
Pre-clinical development of a CDK inhibitor for the treatment of cancer	Completed
Pre-clinical Evaluation of FLT3 Inhibitors for Treatment of Acute Myeloid Leukaemia	Completed
Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer	Completed
Preclinical evaluation of novel dual CDK2/5 inhibitors as anticancer drug candidates	Completed
Targeting prostate cancer cells with elastin like peptide based micelles displaying gastrin releasing peptide	Completed

more less

Dr Hugo Albrecht

About me

About me

UniSA Clinical & Health Sciences

About me

Professional Associations

Experience

Qualifications

Research

Research focus

Projects

Outputs

Highlights

Chapters

Journal Articles

External engagement & recognition

Collaborations

Collaborations

Teaching & student supervision

Highlights

Courses and programs

Courses I teach

Research degree supervision

Gallery